Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares moved up 1.76% in last trading session and ended the day at $93.86. VRX Gross Margin is 75.00% and its has a return on assets of 1.50%. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) quarterly performance is -58.81%.
Reuters on Monday reported the possibility of Valeant Pharmaceuticals International Inc (NYSE:VRX) selling Paragon Vision Sciences, its contact lens manufacturing division. News of the possible sale comes amid the Federal Trade Commission’s scrutiny of Valeant as regulators are concerned that the company has too much control of the contact lens market.
Southwest Airlines Co. (NYSE:LUV) ended the last trading day at $45.04. Company weekly volatility is calculated as 4.11% and price to cash ratio as 9.46. Southwest Airlines Co. (NYSE:LUV) showed a weekly performance of -4.25%.
Southwest Airlines Co. (NYSE:LUV) released its November traffic data and provided fourth quarter guidance. Southwest said that it flew 9.7 billion revenue passenger miles (RPMs) throughout November, marking a 13.9 percent increase from the same month a year ago. The company added that its available seat miles (ASMs) rose 9.7 percent from a year ago to 11.7 billion.
On 08 December, American Capital, Ltd. (NASDAQ:ACAS) shares fell -3.80% and was closed at $14.16. ACAS EPS growth in last 5 year was 19.20%. American Capital, Ltd. (NASDAQ:ACAS) year to date (YTD) performance is -3.08%.
American Capital, Ltd. (NASDAQ:ACAS) announced that its portfolio company Dynojet Research, Inc. (“Dynojet”) was sold to Irving Place Capital and New Value Capital. Established in 1972, Dynojet is a leading manufacturer of aftermarket performance-enhancing parts and accessories as well as diagnostic equipment for powersports vehicles, including motorcycles, ATVs, snowmobiles and automobiles.
Solazyme, Inc. (NASDAQ:SZYM) shares fell -9.27% in last trading session and ended the day at $2.49. SZYM Gross Margin is 60.60% and its has a return on assets of -58.40%. Solazyme, Inc. (NASDAQ:SZYM) quarterly performance is -18.20%.
Solazyme (NASDAQ:SZYM) had its price objective decreased by equities research analysts at Jefferies Group from $7.50 to $5.00 in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. Jefferies Group’s target price would suggest a potential upside of 66.11% from the stock’s previous close.
Repros Therapeutics Inc. (NASDAQ:RPRX) caters to the Healthcare space. Its weekly performance is -20.11%. On the last day of trading company shares ended up at $1.39. Repros Therapeutics Inc. (NASDAQ:RPRX) distance from 50-day simple moving average (SMA50) is 4.96%.
On 1st December, Repros Therapeutics Inc. (NASDAQ:RPRX) announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application for enclomiphene for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. A Complete Response Letter is a communication from the FDA that informs companies that an application cannot be approved in its present form.